MONTREAL, QUEBEC, CANADA--(Marketwire - December 15, 2008) - Theratechnologies (TSX: TH) announced today that the Hart-Scott Rodino Act waiting period has expired with respect to the collaboration and licensing agreement with EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt Germany, for the exclusive rights for the US commercialization of tesamorelin in HIV-associated lipodystrophy. The closing of this transaction is expected to occur this week.
